Trial Profile
A Randomized Phase 2 Study of Vincristine Versus Sirolimus to Treat High Risk Kaposiform Hemangioendothelioma (KHE).
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary) ; Vincristine
- Indications Haemangioendothelioma
- Focus Adverse reactions; Therapeutic Use
- 20 May 2021 Status changed from active, no longer recruiting to discontinued.
- 18 Oct 2019 Status changed from recruiting to active, no longer recruiting.
- 07 Nov 2018 Planned primary completion date changed from 1 Jun 2021 to 1 Sep 2022.